Amolyt Pharma

History

2024: Acquisition by AstraZeneca

On July 15, 2024, AstraZeneca announced the successful completion of the acquisition of medical biotechnology company Amolyt Pharma, specializing in the development of drugs for the treatment of rare endocrine diseases.

Under the terms of the final agreement, AstraZeneca acquired all outstanding Amolyt Pharma shares for a total amount of up to 1.05 billion dollars USA excluding free cash and debt. This includes an advance of  dollars US $800 million at the close of the transaction, as well as the right of Amolyt Pharma shareholders to receive an additional contingent payment of US $250 million, which will be paid upon reaching certain benchmarks. AstraZeneca is looking forward to meeting with employees of Amolyt Pharma.

The acquisition is expected to strengthen Alexion's late-stage product line - AstraZeneca's rare disease division - and expand the franchise to drugs that affect bone metabolism with the investigational (phase III ) therapeutic peptide eneboparatide (AZP-3601), which has a specific mechanism of action and is designed to achieve major therapeutic targets in hypoparathyroidism. Parathyroid hormone (PTH) deficiency in patients with hypoparathyroidism leads to a significant violation of phosphorus-calcium metabolism, which in turn is fraught with life-threatening symptoms and complications, including the development of chronic kidney disease. This program, as well as Amolyt's personnel, experience and line of earlier developments, will allow Alexion to enter the rare endocrine disease market.